HAINAN SHUANGCHENG PHARMACEUTICALS CO., LTD.

Hainan Shuangcheng Pharmaceuticals Co., Ltd.

002693

CNE100001K63

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
5.26 ^CNY	+0.57%		+13.36%	-29.96%

Apr. 29	Hainan Shuangcheng Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 29	Hainan Shuangcheng Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Shuangcheng Pharmaceuticals Europe S.r.l announced that it has received €0.05 million in funding from Hainan Shuangcheng Pharmaceuticals Co., Ltd.

December 07, 2022

On December 8, 2022, Shuangcheng Pharmaceuticals Europe S.r.l closed the transaction.

Latest news about Hainan Shuangcheng Pharmaceuticals Co., Ltd.

Hainan Shuangcheng Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29	CI
Hainan Shuangcheng Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 29	CI
Hainan Shuangcheng Pharma's Unit Gets Green Light to Market Pregabalin Capsules	Mar. 18	MT
Shuangcheng Pharmaceutical Gets Nod to Market Anticoagulant in Saudi Arabia	Mar. 15	MT
Shuangcheng Pharma Unit Passes US FDA On-Site Inspection	Jan. 26	MT
Shuangcheng Pharma Shuangcheng Pharmaceutical Secures Pakistan Approval for Hepatitis, Tumor Drug	Jan. 04	MT
Hainan Shuangcheng Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Shuangcheng Pharma Flags 20 Million Yuan of Unrecovered Financial Products	23-10-05	MT
Hainan Shuangcheng Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI
Shuangcheng Pharma Receives Nod to Produce Aseptic Products in Saudi Arabia	23-07-28	MT
Shuangcheng Pharmaceutical Gets Drug Production License	23-05-12	MT
Hainan Shuangcheng Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
Hainan Shuangcheng Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-20	CI
Shuangcheng Pharma Applies to Have Stomach Drug Added to China’s Drug Procurement Scheme	23-03-30	MT
Hainan Shuangcheng Pharmaceutical Finalizes Transfer of Drug Rights	23-01-12	MT
Hainan Shuangcheng Pharmaceuticals Co., Ltd. Announces Board Appointments	23-01-10	CI
Hainan Shuangcheng Pharmaceuticals Sells Injection Product Rights for 32 Million Yuan	23-01-05	MT
Shuangcheng Pharmaceuticals Europe S.r.l announced that it has received €0.05 million in funding from Hainan Shuangcheng Pharmaceuticals Co., Ltd.	22-12-07	CI
Hainan Shuangcheng Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-27	CI
Hainan Shuangcheng Subsidiary Agrees to Paclitaxel Production	22-09-26	MT
Hainan Shuangcheng Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-12	CI
Hainan Shuangcheng Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-29	CI
Hainan Shuangcheng Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-29	CI
Hainan Shuangcheng Pharmaceuticals Co., Ltd. Elects Bai Jing as Non-Independent Director	22-01-27	CI
Hainan Shuangcheng Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-26	CI

Chart Hainan Shuangcheng Pharmaceuticals Co., Ltd.

Duration

Period

Chart Hainan Shuangcheng Pharmaceuticals Co., Ltd.

More charts

Hainan Shuangcheng Pharmaceuticals Co., Ltd. is a China-based company principally engaged in the production, sale, research and development of chemically synthesized peptide drugs. The Company's main products include Jitai (thymalfasin for injection), for the treatment of various types of liver diseases, cancers, geriatric deseases and infectious diseases; thymopentin for infection; somatostatin, for the treatment of severe acute esophageal variceal bleeding and severe acute stomach or for the adjuvant therapy of duodenal ulcer bleeding and diabetic ketoacidosis, as well as other drugs. The Company distributes its products in domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

2024-08-28 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
HAINAN SHUANGCHENG PHARMACEUTICALS CO., LTD.	-29.96%	303M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+19.98%	43.67B
OTSUKA HOLDINGS CO., LTD.	+20.67%	22.51B
SANDOZ GROUP AG	+14.41%	14.6B
CIPLA LIMITED	+14.32%	13.74B
ZYDUS LIFESCIENCES LIMITED	+44.72%	11.91B
ONO PHARMACEUTICAL CO., LTD.	-8.37%	7.04B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+10.21%	5.42B

Generic Pharmaceuticals

Hainan Shuangcheng Pharmaceuticals Co., Ltd.

Equities

002693

CNE100001K63

Pharmaceuticals

Shuangcheng Pharmaceuticals Europe S.r.l announced that it has received €0.05 million in funding from Hainan Shuangcheng Pharmaceuticals Co., Ltd.

Latest news about Hainan Shuangcheng Pharmaceuticals Co., Ltd.

Chart Hainan Shuangcheng Pharmaceuticals Co., Ltd.

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Generic Pharmaceuticals